Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vasopressin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A known ✓ | P37288 | 7/20 | 0.95 |
| ▸ | AVPR1B known ✓ | P47901 | 5/20 | 0.95 |
| ▸ | AVPR2 known ✓ | P30518 | 4/20 | 0.95 |
| ▸ | OXTR | P30559 | 4/20 | 0.95 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.84 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.76 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.76 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vasopressin SCHEMBL17874853 | 0.97 | AVPR1A (1.00) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| Vasopressin SCHEMBL29688276 | 0.97 | AVPR1A (1.00) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| Vasopressin SCHEMBL19712236 | 0.97 | AVPR1A (1.00) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| Vasopressin SCHEMBL18937546 | 0.97 | AVPR1A (1.00) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| Vasopressin SCHEMBL29530914 | 0.96 | AVPR1A (0.97) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| Lypressin SCHEMBL1650587 | 0.96 | OXTR (0.87) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| Lypressin SCHEMBL33287 | 0.96 | OXTR (0.87) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| SCHEMBL23879427 | 0.95 | AVPR1A (0.96) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| SCHEMBL18476287 | 0.95 | AVPR1A (0.96) | AVPR1AAVPR1BAVPR2OXTRPTGS1 | |
| SCHEMBL24390785 | 0.95 | AVPR1A (0.96) | AVPR1AAVPR1BAVPR2OXTRPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 226 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4622989-A1 | METHOD OF PREPARING VASOPRESSIN | Polypeptide Laboratories Holding (PPL) AB (SE) | 2025-10-01 | — | — | EP | claimed |
| CN-118831137-B | A Chinese medicinal composition for treating cardiovascular and cerebrovascular diseases, and its preparation method | 广东医科大学附属第二医院 | 2025-03-21 | — | — | CN | claimed |
| WO-2024112250-A1 | METHOD OF PREPARING VASOPRESSIN | POLYPEPTIDE LABORATORIES HOLDING (PPL) AB (SE) | 2024-05-30 | — | — | WO | claimed |
| CN-116903705-A | Method for purifying posterior pituitary element | 南京新百药业有限公司 | 2023-10-20 | — | — | CN | claimed |
| WO-2023104027-A1 | YEAST IMMUNE MICRO-NANO BIOROBOT LOADED WITH BLOOD COAGULATION DRUGS, PREPARATION THEREOF AND APPLICATION THEREOF | 深圳先进技术研究院 | 2023-06-15 | — | — | WO | claimed |
| CN-116063580-A | Peptide analogues | 艾得佩索拉公司 | 2023-05-05 | — | — | CN | claimed |
| WO-2023010189-A1 | CYLINDRICAL TUBULAR PROSTHETIC DEVICE, AND PROSTHETIC DEVICE WITH SYSTEM FOR LOCAL RELEASE OF MEDICAMENTS VIA FUNCTIONALISED NANOPARTICLES, MORE SPECIFICALLY LIPOSOMES, WITH CONTROLLED PASSIVE OR ACTIVE RELEASE | MAUES CHRISTIANE DIAS (BR) | 2023-02-09 | — | — | WO | claimed |
| CN-114099466-A | Bionic cell membrane-inner core nano particle and preparation method and application thereof | 国家纳米科学中心 | 2022-03-01 | — | — | CN | claimed |
| CN-122075633-A | Medicine for preventing and treating virus infection and tumor and its application method | — | 2026-05-26 | — | — | CN | disclosed |
| US-12600959-B2 | PH20 polypeptide variants, formulations and uses thereof | HALOZYME, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| US-20260048014-A1 | METHODS AND COMPOSITIONS FOR TARGETED DELIVERY OF PROTEIN FRAGMENTS | SIGNABLOK INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12552736-B2 | Compositions for preventing and/or treating degenerative disorders of the central nervous system and/or lysosomal storage disorders | AMICUS THERAPEUTICS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260015389-A1 | V1A Receptor Partial Agonist and Method of Use | PHARMALN CORP (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250345385-A1 | MIXTURES AND FORMULATIONS COMPRISING AN ALKYL AMMONIUM EDTA SALT | CAMURUS AB (SE) | 2025-11-13 | — | — | US | disclosed |
| EP-2288345-A1 | PSYCHO-PHARMACEUTICALS | University College Dublin National University Of Ireland, Dublin (IE) | 2011-03-02 | — | — | EP | disclosed |
| US-20110034565-A1 | PSYCHO-PHARMACEUTICALS | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2011-02-10 | — | — | US | disclosed |
| WO-2009128058-A1 | PSYCHO-PHARMACEUTICALS | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al (IE) | 2009-10-22 | — | — | WO | disclosed |
| EP-1991212-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | Braincells, Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC (US) | 2007-10-18 | — | — | US | disclosed |
| WO-2007104035-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552736-B2 | Compositions for preventing and/or treating degenerative disorders of the central nervous system and/or lysosomal storage disorders | GBA1, GALC, GBA2 | AVPR1A 2455/4885AVPR1B 2699/4885AVPR2 1804/4885 |
| US-12600959-B2 | PH20 polypeptide variants, formulations and uses thereof | PREP, HM13, MMP20 | AVPR1A 1254/4885AVPR1B 1452/4885AVPR2 1172/4885 |
| US-20260015389-A1 | V1A Receptor Partial Agonist and Method of Use | AVPR1A, AVPR1B, AVPR2 | AVPR1A 1/4885AVPR1B 2/4885AVPR2 3/4885 |
| US-20110034565-A1 | PSYCHO-PHARMACEUTICALS | PNMT, HTR3C, HTR5A | AVPR1A 322/4885AVPR1B 185/4885AVPR2 356/4885 |
| US-20260048014-A1 | METHODS AND COMPOSITIONS FOR TARGETED DELIVERY OF PROTEIN FRAGMENTS | MSR1, CD209, APOB | AVPR1A 4682/4885AVPR1B 4431/4885AVPR2 4818/4885 |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | GAP43, BDNF, DCX | AVPR1A 1398/4885AVPR1B 1228/4885AVPR2 1629/4885 |
| US-20250345385-A1 | MIXTURES AND FORMULATIONS COMPRISING AN ALKYL AMMONIUM EDTA SALT | PHOSPHO1, LIPA, ABHD16A | AVPR1A 593/4885AVPR1B 647/4885AVPR2 1178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.